Connect with us

Technology

10x Genomics Reports First Quarter 2026 Financial Results

Published

on

PLEASANTON, Calif., May 7, 2026 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.

Recent Updates

Revenue was $150.8 million for the first quarter of 2026, representing a 3% decrease over the corresponding period of 2025. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025.Launched Atera, a new platform to redefine how biology is measured and understood. Atera was engineered to deliver spatial whole-transcriptome analysis with single-cell sensitivity at unprecedented scale. The Company expects to start shipping Atera in the second half of 2026.Announced a partnership with Bioptimus, a global AI biotech company, to launch STELA, a multinational spatial data generation initiative to create foundational datasets connecting underlying biology with disease outcomes. The initiative is starting this effort on our Xenium platform and plans to expand to Atera over time.Ended the first quarter of 2026 with cash and cash equivalents and marketable securities of $539.8 million, representing a $112.9 million increase from March 31, 2025.

“We had a solid start to the year, with double-digit growth in Single Cell consumables reaction volumes and double-digit growth in Spatial consumables revenue,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “The biggest highlight is our recent launch of Atera, which represents the most significant product introduction in our history. We are extremely encouraged by the extraordinary early customer response.”

First Quarter 2026 Financial Results

Revenue was $150.8 million for the first quarter of 2026, a 3% decrease from the corresponding period of 2025. Excluding $16.8 million related to a patent litigation settlement recognized in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025.

Gross margin was 70% for the first quarter of 2026, as compared to 68% for the corresponding prior year period. The increase in gross margin was primarily due to lower warranty costs and lower inventory write-downs, partially offset by a decrease in license and royalty revenue reflecting a non-recurring royalty benefit recognized in the first quarter of 2025.

Operating expenses were $123.2 million for the first quarter of 2026, a 15% decrease from $144.8 million for the corresponding prior year period. The decrease was primarily driven by lower outside legal expenses and personnel expenses, partially offset by a non-recurring gain on settlement of $9.2 million recognized in the first quarter of 2025.

Operating loss was $17.0 million for the first quarter of 2026, as compared to operating loss of $39.3 million for the corresponding prior year period.

Net loss was $13.5 million for the first quarter of 2026, as compared to a net loss of $34.4 million for the corresponding prior year period.

Cash and cash equivalents and marketable securities were $539.8 million as of March 31, 2026.

2026 Financial Guidance 

10x Genomics is maintaining its full year 2026 revenue guidance of $600 million to $625 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in 2025, this represents 0% to 4% growth over full year 2025.

Webcast and Conference Call Information

10x Genomics will host a conference call to discuss the first quarter 2026 financial results, business developments and outlook after market close on Thursday, May 7, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “outlook,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “see,” “estimate,” “predict,” “potential,” “would,” “likely,” “seek” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s products, services, business strategy, collaborations and opportunities and 10x Genomics, Inc.’s financial performance and results of operations, including expectations regarding revenue and guidance. These statements are based on management’s current expectations, forecasts, beliefs, estimates, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics’ expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s most recently-filed 10-K for the fiscal year ended December 31, 2025 filed on February 12, 2026 and the company’s quarterly report on Form 10-Q for the quarter ended March 31, 2026 to be filed with the U.S. Securities and Exchange Commission (“SEC”), and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

Investors: investors@10xgenomics.com

Media: media@10xgenomics.com

10x Genomics, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

Three Months Ended
March 31,

2026

2025

Products and services revenue

$      149,896

$      137,823

License and royalty revenue

947

17,060

Revenue (1)

150,843

154,883

Cost of products and services revenue (2)

44,665

49,438

Gross profit

106,178

105,445

Operating expenses:

Research and development (2)

56,847

64,245

Selling, general and administrative (2)

66,377

89,728

Gain on settlement

(9,200)

Total operating expenses

123,224

144,773

Loss from operations

(17,046)

(39,328)

Other income (expense):

Interest income

5,014

3,686

Other income (expense), net

(815)

2,136

Total other income

4,199

5,822

Loss before provision for income taxes

(12,847)

(33,506)

Provision for income taxes

623

852

Net loss

$      (13,470)

$      (34,358)

Net loss per share, basic and diluted

$         (0.10)

$         (0.28)

Weighted-average shares used to compute net loss per share, basic and diluted

128,291,153

122,606,091

__________________________

(1)

The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company’s Visium and Xenium products:

Three Months Ended
March 31,

2026

2025

Instruments

Single Cell

$         5,223

$         5,913

Spatial

6,039

8,902

Total instruments revenue

11,262

14,815

Consumables

Single Cell

88,894

84,109

Spatial

40,907

31,247

Total consumables revenue

129,801

115,356

Services

8,833

7,652

Products and services revenue

149,896

137,823

License and royalty revenue

947

17,060

Total revenue

$      150,843

$      154,883

(1)

The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):

Three Months Ended
March 31,

2026

2025

Americas

United States*

$       76,693

$       86,818

Americas (excluding United States)

3,406

3,752

Total Americas

80,099

90,570

Europe, Middle East and Africa

36,852

31,895

Asia-Pacific

China

15,837

16,883

Asia-Pacific (excluding China)

18,055

15,535

Total Asia-Pacific

33,892

32,418

Total revenue

$      150,843

$      154,883

*

Includes license and royalty revenue.

(2)

Includes stock-based compensation expense as follows:

Three Months Ended
March 31,

(in thousands)

2026

2025

Cost of revenue

$         1,918

$         2,481

Research and development

10,695

14,106

Selling, general and administrative

10,029

14,489

Total stock-based compensation expense

$       22,642

$       31,076

 

10x Genomics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)

March 31,
2026

December 31,
2025

Assets

Current assets:

Cash and cash equivalents

$      490,285

$      473,966

Marketable securities

49,563

49,443

Accounts receivable, net

39,031

47,013

Other receivables

17,106

35,480

Inventory

53,487

56,341

Prepaid expenses and other current assets

20,261

22,208

Total current assets

669,733

684,451

Property and equipment, net

220,591

226,711

Operating lease right-of-use assets

58,390

60,450

Goodwill

4,511

4,511

Intangible assets, net

59,910

62,329

Other noncurrent assets

2,624

2,913

Total assets

$    1,015,759

$    1,041,365

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$       17,425

$       12,733

Accrued compensation and related benefits

21,506

42,500

Accrued expenses and other current liabilities

33,680

39,971

Deferred revenue

24,342

23,902

Operating lease liabilities

11,330

10,985

Contingent consideration, current

5,315

23,363

Total current liabilities

113,598

153,454

Contingent consideration, noncurrent

1,222

1,237

Operating lease liabilities, noncurrent

70,059

73,376

Deferred revenue, noncurrent

10,138

10,501

Other noncurrent liabilities

6,418

6,471

Total liabilities

201,435

245,039

Commitments and contingencies

Stockholders’ equity:

Preferred stock

Common stock

2

2

Additional paid-in capital

2,338,269

2,306,690

Accumulated deficit

(1,524,061)

(1,510,591)

Accumulated other comprehensive income

114

225

Total stockholders’ equity

814,324

796,326

Total liabilities and stockholders’ equity

$    1,015,759

$    1,041,365

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-reports-first-quarter-2026-financial-results-302766095.html

SOURCE 10x Genomics, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

AIA Contract Documents Launches AI Assistant and Names Arijit “AJ” Saha Chief Technology Officer

Published

on

By

GREENVILLE, S.C., Aug. 26, 2026 /PRNewswire/ — AIA Contract Documents (ACD), the industry standard for construction agreements that support $100 billion in contract value each year, today announced the launch of its AI Assistant, providing in-app contract guidance, alongside an enhanced contract editing experience to accelerate contracting workflows.

The company also announced the hiring of Arijit “AJ” Saha as Chief Technology Officer to lead ACD’s technology and AI strategy and continue accelerating its innovation and value to customers.

Saha brings over 23 years of experience leading engineering, data, AI and cloud technology teams across emerging companies and large enterprises, including Infosys, Goldman Sachs, Noodle AI (now Daybreak), and most recently Redica Systems, where he served as Chief Technology Officer.

At ACD, Saha will advance the next generation of tools that streamline critical workflows across the construction lifecycle, helping architecture, engineering, and construction (AEC) firms align teams, manage risk, and move projects forward from start to completion.

“We are elevating our technology and our talent at the same time,” said Nick Macey, CEO of ACD. “Our latest contract workflows and AI capabilities mark significant milestones for our customers, and with AJ’s leadership, we’re building on that momentum to deliver solutions that help firms reduce contract disputes and achieve faster alignment during negotiations while driving more predictable outcomes.”

With more than 300 standardized contract documents as its foundation, ACD is modernizing the experience around them so project teams can move from template to signed agreement with less effort. The newly upgraded editor is designed to support a simpler document workflow, and the new AI Assistant provides on-demand guidance when users request it at any point in the contracting process. Additional AI capabilities are being developed to further help customers assess project risk and complete contract-related tasks more efficiently.

“ACD has earned the trust of the industry for nearly 140 years,” said Saha. “That foundation creates a rare opportunity to build intelligent, AI-native products that help project teams work with greater speed and clarity. I’m excited to lead this next chapter of innovation at ACD to deliver even more valuable tools for our customers.”

With more than 45,000 companies using ACD to write over 1.2 million contracts each year, the company supports a foundational part of how construction projects across the country come together. These investments build on that foundation, combining trusted industry expertise with modern technology to help AEC firms navigate increasingly complex projects and manage risk more effectively.

About AIA Contract Documents (ACD) 

For nearly 140 years, AIA Contract Documents (ACD) has supported architecture, engineering, and construction professionals by delivering a shared industry standard to align parties on a project. What began in 1888 with the development of standardized construction contracts has evolved into a comprehensive suite of contract tools and foundational workflows that not only shape how the industry works today but also help firms navigate construction’s growing complexity.  In a world driven by scale, fragmentation, and increasingly rapid decision-making, ACD serves as a trusted anchor, bringing stability and clarity that keep construction projects moving. To learn more, visit aiacontracts.com and follow us on LinkedIn

View original content to download multimedia:https://www.prnewswire.com/news-releases/aia-contract-documents-launches-ai-assistant-and-names-arijit-aj-saha-chief-technology-officer-302860669.html

SOURCE AIA Contract Documents

Continue Reading

Technology

Rentana Launches Ask Rentana, Giving Every Multifamily Team Member the Power of an Analyst

Published

on

By

New capability answers complex portfolio questions in seconds, placing powerful analysis directly in the hands of executives, revenue leaders and property teams, with real gains to show for it.

DALLAS, Aug. 26, 2026 /PRNewswire/ — Rentana, the AI-powered revenue intelligence platform for multifamily owners and operators, this summer announced the general availability of Ask Rentana, giving everyone across a real estate organization the ability to analyze portfolio performance and answer complex operational questions in seconds.

New capability answers complex portfolio questions in seconds, giving powerful analysis to multifamily teams.

“I use Ask Rentana as my everyday AI analyst. It’s remarkable,” said a Director of Revenue Management at an NMHC Top 10 Property Manager. “Analytical work that used to take hours, such as reforecasting a lease-up absorption schedule, now takes minutes, which frees us to focus on strategy rather than data assembly.”

For years, answers to important questions were delayed because analysis could only be done by a few experts trained in the use of complex tools. Traditional dashboards show what already happened. Now, teams can see what’s likely to happen next and take action to influence it, long before it becomes reality. The future becomes something they help shape, not something that happens to them.

Executives walk into meetings already briefed on where things stand and where they’re headed. Revenue leaders act directly on what a prediction reveals, closing the gap between seeing a trend and doing something about it. Onsite teams take an active hand in shaping the future in front of them.

What Leaders Are Saying

“As the leading Rentana user on our team, I’m using Ask Rentana as an analytical engine for ownership reporting, executive briefings and communicating our revenue strategy clearly to the broader team so everyone is bought in,” said Rex Miljus, The Collier Companies.

Power users are already averaging more than ten Ask Rentana conversations per week. Viewers, property managers and other non-revenue-manager roles now make up 72% of everyone using Ask Rentana, evidence that this intelligence is reaching well past the revenue team’s desk.

Executives are getting immediate value from Ask Rentana.

“As a CEO, I use Ask Rentana to brief myself on portfolios and specific properties, set clear goals and monthly targets for my team, and pressure-test trade-offs before I walk into the room,” said Chris Urso, CEO, URS Capital Partners. “It also helps me translate the numbers into something my team can rally around, connecting occupancy and pricing decisions to the actual revenue impact. Ask Rentana gives my team those capabilities on demand, any day, any time.”

Ask Rentana makes it easy to share the story your data is telling, synthesizing portfolio analysis, evaluating relationships across performance metrics, and identifying the real drivers and trade-offs behind a number, not just the number itself. That holds true across absorption, retention, concessions, closing ratios and property performance, each analyzed immediately, with the full analysis downloadable directly from the conversation to share with stakeholders.

Complex Analysis in Seconds With Enterprise-Grade Security and Privacy

Analysis that previously took days now happens instantly. Even a single question with complex layers, spanning pricing, leasing and property performance all at once, would typically take a skilled analyst hours of deep, cross-functional analysis. With Ask Rentana, it comes back complete in seconds: reasoning explained, interactive charts and tables included, and specific next steps for the team on the ground.

“AI is fundamentally changing who gets to work with data inside a real estate organization,” said Julie Blanc, Co-Founder and CEO of Rentana. “C-suites are getting answers faster, revenue teams can investigate questions that previously took hours or days, and property teams have access to insights they’ve never had before. Ask Rentana gives everyone on the team the power of an analyst, while keeping the judgment behind every decision exactly where it belongs, with the people making it.”

Security and privacy are built into the product. Every Ask Rentana conversation operates inside a private environment built around that customer’s own data. Customers’ private data is never shared with or drawn from another customer’s portfolio. Customers do not need to provide any additional data beyond what they already share with the Rentana platform. Rentana is SOC 2 Type II certified.

Ask Rentana is available now to all Rentana customers at no additional cost.

About Rentana
Rentana is an AI-powered revenue intelligence platform purpose-built for multifamily owners and operators. Founded by alumni of category-defining companies including Stripe, Airtable and Airbnb, Rentana is trusted by multiple members of the NMHC Top 50, holds a 4.9 rating on G2, and is ranked the #1 Revenue Management platform on Revyse. Book a demo at rentana.io/demo.

Media Contact:
press@rentana.io 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rentana-launches-ask-rentana-giving-every-multifamily-team-member-the-power-of-an-analyst-302860161.html

SOURCE Rentana, Inc.

Continue Reading

Technology

WonderBotz Debuts at No. 2,421 on the 2026 Inc. 5000 with 137% Three-Year Growth

Published

on

By

First-time honoree grew its client base 220% on Agentic Process Management — running AI, automation, and people to outcomes clients can measure

PRINCETON, N.J., Aug. 26, 2026 /PRNewswire-PRWeb/ — WonderBotz today announced it has been ranked No. 2,421 on the 2026 Inc. 5000, Inc. magazine’s annual list of America’s fastest-growing private companies. The company earned its first appearance on the list with 137% revenue growth from 2022 to 2025 and a 220% increase in client logos over the same period.

“Anyone can make automation promises. Our clients pay us to be accountable for the impact delivered after go-live. That’s Agentic Process Management, and it’s why we’re on this list.” – Steve LaValle, Co-Founder and Co-CEO of WonderBotz

The growth tracks a shift in what enterprises buy. Over the past three years, WonderBotz’s clients moved AI and automation out of pilots and into governed production, and paid-for outcomes they could measure after go-live, not activity before it. WonderBotz calls the discipline behind that shift Agentic Process Management (APM): orchestrating AI, automation, and people into business outcomes an enterprise can hold its partner accountable for. One healthcare provider cut back-office processing time 90% and held WonderBotz to that result long after launch.

“The Inc. 5000 is the one award you can’t spin. It’s built on nothing but revenue, and revenue is clients voting with their budgets,” said Steve LaValle, Co-Founder and Co-CEO of WonderBotz. “Anyone can make automation promises. Our clients pay us to be accountable for the impact delivered after go-live. That’s Agentic Process Management, and it’s why we’re on this list.”

That accountability runs through WonderBotz AlwayzOn, our managed service that keeps a client’s Agents, AI, and Botz governed, orchestrated, and always working after go-live: infrastructure support, governance and security controls, an AI command center, and build capacity, delivered across a platform ecosystem spanning UiPath, SS&C Blue Prism, Microsoft, Tungsten Automation and Anthropic, among others. Details at wonderbotz.com/platforms/wonderbotz-alwayzon-managed-services.

“Launch day is the easy day. Day ninety is when every dashboard is green and the work has quietly stopped serving the business,” said Bhavyesh Virani, Co-Founder and Co-CEO of WonderBotz. “That’s drift, and you can’t catch it from a dashboard, because the dashboard is what’s reassuring you. WonderBotz AlwayzOn exists to catch it before your CFO does.”

The Inc. 5000 is the most prestigious ranking of the nation’s fastest-growing private companies; past honorees include Microsoft, Meta, Chobani, Oracle, and Patagonia. Among this year’s honorees, the median three-year revenue growth rate was 130%, and together they added more than 627,208 jobs to the U.S. economy over the past three years.

“Every company on the Inc. 5000 has a story of perseverance, smart decision making, and a refusal to sit still,” says Mike Hofman, editor-in-chief of Inc. “Their growth reflects more than strong financial performance–it reflects creativity, resilience, and the customer focus required to build companies that make a lasting impact. We congratulate all honorees on this significant achievement.”

Inc. will celebrate the honorees at the 2026 Inc. 5000 Conference & Gala, October 14–16 in Dallas, Texas; the top 500 companies will appear in the Fall issue of Inc. magazine. For the full Inc. 5000 list, honoree company profiles, and a searchable database by industry and location, visit www.inc.com/inc5000.

About WonderBotz

WonderBotz is an agentic operating company and the team behind Agentic Process Management (APM), the operating discipline for orchestrating AI, automation, and people into measurable business outcomes. Founded in 2017 by former Big Four leaders, WonderBotz helps enterprises launch, modernize, and manage intelligent operations without forcing a complete technology replacement. WonderBotz AlwayzOn managed services keep a client’s Agents, AI, and Botz governed, orchestrated, and always on. WonderBotz serves mid-market to Fortune 100 clients across banking, insurance, healthcare, manufacturing, and retail, with delivery operations in the U.S. and India. Learn more at wonderbotz.com.

About Inc.

Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com.

Inc. 5000 List Methodology

Companies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2022 to 2025. To qualify, companies must have been founded and generating revenue by March 31, 2022. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2025. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2022 is $100,000; the minimum for 2025 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons.

Media Contact

Paula Carneiro Cox, WonderBotz, 1 702 834 7205, paula.carneiro@wonderbotz.com, https://wonderbotz.com/

View original content to download multimedia:https://www.prweb.com/releases/wonderbotz-debuts-at-no-2-421-on-the-2026-inc-5000-with-137-three-year-growth-302858605.html

SOURCE WonderBotz

Continue Reading

Trending